
    
      Will not be included in CR1 nor the patients with good forecast under chemotherapy, (Inv 16;
      t(8;21)), nor patients at the very high risk of relapse (anomalies complex cytogenetics). The
      conditioning of MA graft will be Cyclophosphamide and ICT with strong amounts. NMA graft will
      be made according to the protocol Seattle (fludarabine 30 mg/m2/j X 3 and ICT of 2 Gy). The
      study will be undertaken in 12 French centers of allograft taking part in the protocols
      ESPARTO or EORTC.
    
  